Evidence map›Paper›PMID 27294002›Full record

ArticleAmerican journal of cancer research2016

LncRNA MALAT1 exerts oncogenic functions in lung adenocarcinoma by targeting miR-204.

Jipeng Li, Jianhua Wang, Yin Chen, Shanfeng Li, Mingwei Jin, Huaying Wang, Zhe Chen, Wanjun Yu

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 3 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 3 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. A genome-wide CRISPR activation screen identifiesFrontiers in molecular biosciences · 2023
    Article
  16. Review
  17. Article
  18. Review
  19. Frontiers in genetics · 2022
    Article
  20. Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jipeng LiDepartment of Central Laboratory, Yinzhou People's Hospital Ningbo 315040, China.
Jianhua WangDepartment of Central Laboratory, Yinzhou People's Hospital Ningbo 315040, China.
Yin ChenDepartment of Central Laboratory, Yinzhou People's Hospital Ningbo 315040, China.
Shanfeng LiDepartment of Central Laboratory, Yinzhou People's Hospital Ningbo 315040, China.
Mingwei JinDepartment of Central Laboratory, Yinzhou People's Hospital Ningbo 315040, China.
Huaying WangDepartment of Respiratory and Critical Care Medicine, Yinzhou People's Hospital Ningbo 315040, China.
Zhe ChenDepartment of Central Laboratory, Yinzhou People's Hospital Ningbo 315040, China.
Wanjun YuDepartment of Respiratory and Critical Care Medicine, Yinzhou People's Hospital Ningbo 315040, China.
Ningbo No. 2 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence indicates that the lncRNAs play a critical role in cancer progression and metastasis. In this study, we found that MALAT1 upregulation was associated with larger tumor size and lymph-node metastasis, and also correlated with shorter overall survival of lung adenocarcinoma patients. Furthermore, MALAT1 promotes EMT and metastasis of lung adenocarcinoma cells in vitro and in vivo. In particular, MALAT1 upregulated the expression of miR-204 target gene SLUG through competitively 'spongeing' miR-204. In summary we unveil a branch of the MALAT1/miR-204/SLUG pathway that regulates the progression of lung adenocarcinoma.

Indexed as

Lung adenocarcinomaMALAT1miR-204SLUG

Identifiers

PMID27294002
PMCPMC4889723
OpenAlexW2473555904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.